Next Article in Journal
A Canadian Perspective on the Challenges for Delivery of Curative-Intent Therapy in Stage III Unresectable Non-Small Cell Lung Cancer
Previous Article in Journal
Artificial Intelligence in Colorectal Cancer Screening, Diagnosis and Treatment. A New Era
Open AccessArticle

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features

by 1, 1 and 1,2,*
1
Department of Pathology, University of Texas Southwestern Medical Center, 6201 Harry Hines Blvd, Dallas, TX 75235, USA
2
Harold C. Simmons Cancer Center, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75235, USA
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2021, 28(3), 1608-1617; https://doi.org/10.3390/curroncol28030150
Received: 4 March 2021 / Revised: 11 April 2021 / Accepted: 20 April 2021 / Published: 24 April 2021
Human epidermal growth factor receptor 2 (HER2) positive (+) classical type invasive lobular carcinoma (cILC) of the breast is extremely rare and its clinicopathologic features have not been well characterized. We compared features of HER2(+) and HER2 negative (−) cILCs. A total of 29 cases were identified from the clinical database at our institution from 2011-2019; 9 were HER2(+) cILC tumors and 20 were HER2(−) cILC tumors. The results reveal that HER2(+) cILC group had significantly increased Ki-67 expression and reduced estrogen receptor (ER) expression compared to HER2(−) cILC group (both p < 0.05). In addition, HER2(+) cILCs tended to be diagnosed at a younger age and more common in the left breast, and appeared to have a higher frequency of nodal or distant metastases. These clinicopathologic features suggest HER2(+) cILC tumors may have more aggressive behavior than their HER2(−) counterpart although both groups of tumors showed similar morphologic features. Future directions of the study: (1) To conduct a multi-institutional study with a larger case series of HER2(+) cILC to further characterize its clinicopathologic features; (2) to compare molecular profiles by next generation sequencing (NGS) assay between HER2(+) cILC and HER2(−) cILC cases to better understand tumor biology of this rare subset of HER2(+) breast cancer; and (3) to compare molecular characteristics of HER2(+) cILC and HER2(+) high grade breast cancer in conjunction with status of tumor response to anti-HER2 therapy to provide insight to management of this special type of low grade breast cancer to avoid unnecessary treatment and related toxicity View Full-Text
Keywords: invasive lobular carcinoma; classical type; HER2; ER; Ki-67 invasive lobular carcinoma; classical type; HER2; ER; Ki-67
Show Figures

Figure 1

MDPI and ACS Style

He, L.; Araj, E.; Peng, Y. HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features. Curr. Oncol. 2021, 28, 1608-1617. https://doi.org/10.3390/curroncol28030150

AMA Style

He L, Araj E, Peng Y. HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features. Current Oncology. 2021; 28(3):1608-1617. https://doi.org/10.3390/curroncol28030150

Chicago/Turabian Style

He, Lin; Araj, Ellen; Peng, Yan. 2021. "HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features" Curr. Oncol. 28, no. 3: 1608-1617. https://doi.org/10.3390/curroncol28030150

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop